Stent Thrombosis After Percutaneous Coronary Intervention: From Bare-Metal to the Last Generation of Drug-Eluting Stents.
Polimeni A, Sorrentino S, Spaccarotella C, Mongiardo A, Sabatino J, De Rosa S, Gori T, Indolfi C.
Interv Cardiol Clin. 2022 Oct;11(4):465-473. doi: 10.1016/j.iccl.2022.07.002.
Stent Thrombosis After Percutaneous Coronary Intervention: From Bare-Metal to the Last Generation of Drug-Eluting Stents.
Polimeni A, Sorrentino S, Spaccarotella C, Mongiardo A, Sabatino J, De Rosa S, Gori T, Indolfi C.
Cardiol Clin. 2020 Nov;38(4):639-647. doi: 10.1016/j.ccl.2020.07.008. Epub 2020 Sep 17.
In-Stent Restenosis.
Kawai K, Virmani R, Finn AV.
Interv Cardiol Clin. 2022 Oct;11(4):429-443. doi: 10.1016/j.iccl.2022.02.005. Epub 2022 Sep 24.
Antibody-mediated PCSK9 neutralization worsens outcome after bare-metal stent implantation in mice.
Puspitasari YM, Ministrini S, Liberale L, Vukolic A, Baumann-Zumstein P, Holy EW, Montecucco F, Lüscher TF, Camici GG.
Vascul Pharmacol. 2023 Dec;153:107170. doi: 10.1016/j.vph.2023.107170. Epub 2023 Aug 31.
Italian Multicenter Registry of Bare Metal Stent Use in Modern Percutaneous Coronary Intervention Era (AMARCORD): A multicenter observational study.
Giannini F, Pagnesi M, Campo G, Donahue M, Ferri LA, Briguori C, Stefanini GG, Scardala R, Sardella G, De Rosa S, Figini F, Monello A, Pastormerlo LE, Testa L, Nicolino A, Ielasi A, Durante A, Leone A, Tzanis G, Mangieri A, Ciccarelli G, Briani M, Reimers B, Ceccacci A, Indolfi C, Sheiban I, Palmieri C, Bedogni F, Tespili M, Latib A, Gallo F, Colombo A.
Catheter Cardiovasc Interv. 2021 Feb 15;97(3):411-420. doi: 10.1002/ccd.28798. Epub 2020 Mar 21.
Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention.
Correa-Sadouet C, Rodríguez-Granillo AM, Gallardo C, Mieres J, Fontana L, Curotto MV, Wainer P, Allende NG, Fernández-Pereira C, M Vetulli H, la Hoz RP, Kastrati A, Rodríguez AE; ORCA investigators.
Future Cardiol. 2021 Jul;17(4):539-547. doi: 10.2217/fca-2020-0161. Epub 2020 Nov 11.
Non-Fasting Hypertriglyceridemia as an Independent Risk Factor for Coronary In-Stent Restenosis after Primary Bare Metal Stent Implantation in Patients with Coronary Artery Disease.
Yoshimura M, Umemoto S, Kawano R, Hiromoto M, Yamada M, Fujimura T, Tanaka M, Nao T, Miura T, Yano M.
Int Heart J. 2021;62(5):970-979. doi: 10.1536/ihj.21-015.
Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.
Kornowski R, Konigstein M, Jonas M, Assali A, Vaknin-Assa H, Segev A, Danenberg H, Halabi M, Roguin A, Kerner A, Lev E, Karamasis GV, Johnson TW, Anderson R, Blaxill J, Jadhav S, Hoole S, Witberg G, Issever MO, Ben-Yehuda O, Baumbach A.
J Am Heart Assoc. 2024 Jan 16;13(2):e029051. doi: 10.1161/JAHA.122.029051. Epub 2024 Jan 12.
The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
Alsidawi S, Effat M, Rahman S, Abdallah M, Leesar M.
Cardiovasc Ther. 2015 Dec;33(6):360-6. doi: 10.1111/1755-5922.12160.
Systemic immunosuppressive therapy with oral Sirolimus after bare metal stent implantation: the missing alternative in the prevention of coronary restenosis after percutaneous coronary interventions.
Rodriguez AE, Fernandez-Pereira C.
Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):201-8. doi: 10.2174/157489008786263998.
